BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
09 nov. 2023 08h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Westport, CT, Nov. 9, 2023 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to...
BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP
07 nov. 2023 08h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Westport, CT, November 7, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company...
BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care
02 nov. 2023 08h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Nov. 02, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and...
BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI
01 nov. 2023 08h30 HE
|
BioSig Technologies, Inc.
Westport, CT, Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and...
Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States
31 oct. 2023 08h57 HE
|
Stereotaxis, Inc.
Stereotaxis (NYSE: STXS) & Abbott (NYSE:ABT) announce the first patients in the US have been treated successfully utilizing combined technologies
Heart Failure Therapeutics Market Size, Leading Players, Growth Trends, Forecasts, and Share Analysis 2023-2030 | RationalStat
12 sept. 2023 06h00 HE
|
Rationalstat LLC
Wilmington, Delaware, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Global Heart Failure Therapeutics Market was valued at US$ 6.7 billion in 2022 and is expected to grow at a significant CAGR of 9.1% over the...
BioSig AI Sciences Achieves Infrastructure and Technology progress in Development of Generative AI Platform for Hospitals
24 août 2023 10h30 HE
|
BioSig Technologies, Inc.
Westport, CT, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to...
BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations
23 août 2023 08h30 HE
|
BioSig Technologies, Inc.
Westport, CT, Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to...
BioSig's PURE EP™ Platform Debuts New Automated Features in First Patient Cases
22 août 2023 08h00 HE
|
BioSig Technologies, Inc.
Westport, CT, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to...
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
16 août 2023 08h00 HE
|
Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...